MDM2 and chronic myelogenous leukemia, BCR-ABL1 positive: In conclusion, we have shown that MDM2 inhibitor JNJ-165 induces cell death in a variety of CML cell lines with p53 mutation, including those resistant to Imatinib and harboring T315I mutation.